Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib in Severe COVID-19 Pneumonia
NCT04334044Phase 2Completed
- Sponsor
- PETHEMA
- Start
- Sep 2020
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ruxolitinib in coronavirus disease 2019 (COVID-19), severe acute respiratory syndrome (SARS), sponsored by PETHEMA. Started Sep 2020; status: completed.
02
Drugs
03
Conditions
coronavirus disease 2019 (COVID-19)severe acute respiratory syndrome (SARS)
Beyond the preview
Go deeper on NCT04334044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04334044.